Keros Therapeutics (NASDAQ:KROS) Announces Earnings Results

Keros Therapeutics (NASDAQ:KROS – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.15), Briefing.com reports. During the same quarter in the previous year, the company earned ($0.68) EPS.

NASDAQ:KROS opened at $50.49 on Friday. The company has a 50-day moving average of $56.20 and a 200-day moving average of $53.57. Keros Therapeutics has a 52 week low of $28.50 and a 52 week high of $68.29.

In related news, insider Jennifer Lachey sold 2,650 shares of Keros Therapeutics stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $53.38, for a total transaction of $141,457.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Christopher Rovaldi sold 1,728 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 6th. The shares were sold at an average price of $65.00, for a total transaction of $112,320.00. The disclosure for this sale can be found here. Insiders have sold a total of 20,278 shares of company stock valued at $1,201,417 over the last ninety days. 36.10% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its position in Keros Therapeutics by 129.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 119,298 shares of the company’s stock valued at $6,980,000 after acquiring an additional 67,389 shares in the last quarter. Morgan Stanley increased its position in Keros Therapeutics by 249.1% in the 3rd quarter. Morgan Stanley now owns 80,212 shares of the company’s stock valued at $3,173,000 after acquiring an additional 57,232 shares in the last quarter. BlackRock Inc. increased its position in Keros Therapeutics by 4.2% in the 4th quarter. BlackRock Inc. now owns 1,286,526 shares of the company’s stock valued at $75,277,000 after acquiring an additional 52,368 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in Keros Therapeutics in the 4th quarter valued at about $2,786,000. Finally, Geode Capital Management LLC increased its position in Keros Therapeutics by 20.2% in the 4th quarter. Geode Capital Management LLC now owns 255,747 shares of the company’s stock valued at $14,963,000 after acquiring an additional 42,941 shares in the last quarter. 74.82% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have weighed in on KROS shares. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, March 10th. Zacks Investment Research raised shares of Keros Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Buy” and an average price target of $76.25.

About Keros Therapeutics (Get Rating)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.

Read More